All In Biotech

Drug Trial Radar · NCT07331402

A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

A Random, Single Blind, Positive Control, Crossover Design Clinical Study to Evaluate the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Dec 30, 2025

Study completion Aug 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a random, single blind, positive control, crossover design clinical study to evaluate the pharmacokinetics and pharmacodynamics of HSK39004 inhalation suspension in COPD patients

Conditions

  • COPD Patients

Interventions

  • HSK39004 inhalation suspensionDrug

    HSK39004 inhalation suspension , Inhale through the mouth, 3mg each time, twice a day; Ohtuvayre inhalation suspension, Inhale through the mouth, 3mg each time, twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Cmax after single administrationsTime frame: [Time Frame: From the start of administration to 12 hours post-dose]
  2. The Css(max) after multiple administrations (steady state)Time frame: [Time Frame: From the start of administration to 7 days post-dose]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 36 Sanhao Street, Heping District, Shenyang, Liaoning,China

    Shenyang, Liaoning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.